Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
Pablo Tolosa(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Yolanda Ruano(Hospital Virgen de la Salud), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), A. Rodríguez(European Commission), Manuel Alva(Hospital Universitario 12 De Octubre), Agustín Sánchez-Belmonte, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Cristina Hernándo(Hospital Clínico Universitario de Valencia), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Jordi Canes, Lucía Parrilla, Fernando Salvador(Solti), Javier David Benítez Fuentes(Universidad de Zaragoza), María Cobos-Fernández(Hospital Universitario 12 De Octubre), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Isabel García-Fructuoso(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Ana Maria Roncero Sanchez(Research Institute Hospital 12 de Octubre), Aleix Prat(Hospital Clínic de Barcelona), Ainhoa Madariaga(Hospital Universitario 12 De Octubre), María Fernández(Hospital Universitario Ramón y Cajal), Sònia Servitja(Hospital Del Mar), Laura Lema(Hospital Universitario 12 De Octubre), Marcos Malumbres(Institució Catalana de Recerca i Estudis Avançats)
Cited by 10
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k